EyePoint Pharmaceuticals Inc (EYPT)
7.25
-0.29 (-3.85%)
USD |
NASDAQ |
Jun 24, 16:00
7.25
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 246.84M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -23.84% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.940 |
| Price to Book Value | 1.480 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2373 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 92.21% |
News
Headline
Wire
Time (ET)
Yahoo
06/23 10:00
MT Newswires
06/21 08:26
SA Breaking News
06/21 08:15
Globe Newswire
06/16 07:00
Globe Newswire
06/10 07:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/04/2022* | -- | Results | Q2 2022 | -- | -0.55 | -- | |
| 08/04/2022* | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | -0.52 | -0.59 | 11.16% | |
| 05/04/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/03/2022 | -- | Results | Q4 2021 | -0.59 | -0.51 | -15.12% | |
| 03/03/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/03/2021 | -- | Results | Q3 2021 | -0.58 | -0.41 | -43.21% | |
| 11/03/2021 | 08:30 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S. |
| URL | https://www.eyepointpharma.com |
| Investor Relations URL | http://investors.eyepointpharma.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Aug. 04, 2022 (est.) |
| Last Earnings Release | May. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 24, 2022.
Fundamentals
| Revenue (TTM) | 38.91M |
| Total Expenses (TTM) | 101.54M |
| Net Income (TTM) | -67.11M |
| Total Assets (Quarterly) | 244.56M |
| Total Liabilities (Quarterly) | 77.74M |
| Shareholders Equity (Quarterly) | 166.82M |
| Cash from Operations (TTM) | -55.16M |
| Cash from Investing (TTM) | -89.56M |
| Cash from Financing (TTM) | 107.68M |
Ratings
Profile
Edit
| EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S. |
| URL | https://www.eyepointpharma.com |
| Investor Relations URL | http://investors.eyepointpharma.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Aug. 04, 2022 (est.) |
| Last Earnings Release | May. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| FRBRX | 11.32M USD | 1.43% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| EYPT Tweets |